Evidence map›Paper›PMID 40041178›Full record

ArticleFrontiers in public health2025

The impact of the relationship between government and pharmaceutical enterprises on social contribution during the public health emergency: an empirical study.

Qian Zhuang, Huan Wang, Qiqi Bai, Jingwen Liang

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Qian ZhuangSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Huan WangSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Qiqi BaiSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Jingwen LiangSchool of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: During the COVID-19 pandemic, vaccines and specific drugs are seen as indispensable solutions to ending or responding to the pandemic, and pharmaceutical enterprises are in the spotlight. The Chinese government has made active efforts to guide pharmaceutical enterprises to make appropriate social contribution during the public health emergency. This study explores how government-enterprise relationship promotes this process. Methods: Using the financial and textual data of China's listed pharmaceutical companies and policy data from the official website of the Chinese health-related government departments, this study drew the social contribution through text analysis, and established the response index of pharmaceutical companies to the government-the government-enterprise alignment index ( Results: This study found the more responsive pharmaceutical companies were to government, the greater their contribution to society during the pandemic, mainly through increasing the intensity of drug R&D, production and promotion, and the good communication mechanism between the two formed a mediating effect. Discussion: The nature of state ownership, the presence of embedded party organizations, and the location in the provincial capital city had significant effects on the realization of a high level of government-enterprise alignment positively affecting the social contribution. This study confirms that the Chinese government has made enterprises a part of social governance, which is a global hotspot, through the embedding of party organizations. It also indicates that the government needs to re-recognize its key role in shaping social contribution, especially in distinguishing its responsibilities between normal and emergency situations.

Indexed as

COVID-19Drug IndustryGovernmentPublic HealthChinaEmpirical ResearchHumansPandemicsSARS-CoV-2communication mechanismgovernment-enterprise alignmentparty organizationpublic health emergencysocial contribution

Identifiers

PMID40041178
PMCPMC11876166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.